Last edition
News about "bepirovirsen treatment "
GSK Receives Japan's First Approval for Bepirovirsen as Functional Cure for Chronic Hepatitis B
Japan’s MHLW approves Hibsago for eligible adults with chronic hepatitis B, following Phase 3 data showing a 19 percent functional cure rate after six months of treatment.
Bepirovirsen Treatment | 25/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members